2016 Review: Rapid Change Defines China Regulatory Environment
If you missed some of the many significant events in China’s policy and regulatory landscape in 2016, here is your opportunity to catch up on month-by-month developments.
You may also be interested in...
If the year of the Monkey is a jumpy ride filled with uncertainties, the coming year of the Rooster will be certain to bring more changes to the pharma sector and immuno-oncology, high-end devices and combining artificial intelligence with next-generation genomics are attracting large amount of hot cash inflow.
A shift in dispensing from hospitals to external pharmacies has led to predictions that the direct-to-patient sales model will be big in China. But only those with the right partnerships and expertise will reap the benefits, leading pharmacy chain executives told a recent conference.
Pharma executives in China may soon get an earful of the name Sanming, as the populist healthcare reform model that began at the small city in Fujian is rolled out nationwide and impacts profoundly how drugs are tendered, priced and distributed.